Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of 1,550 and 755 Laser in a Split-face Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03988049
Recruitment Status : Active, not recruiting
First Posted : June 17, 2019
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
David Smart, University of Utah

Brief Summary:
Clinical Trial comparing the 1,550-nanometer fractionated photothermolysis system laser to the 755 nanometer picosecond laser using a split-face (Right-Left) comparison. Patients will receive laser treatments at week 0, week 4, and week 8. Photographs will be taken prior to laser treatment at each visit, and at the week 24 follow-up visit. Photographs will be reviewed by blinded assessors to rate each side of the face and change from baseline photos.

Condition or disease Intervention/treatment Phase
Acne Scars - Mixed Atrophic and Hypertrophic Device: 1,550 fracionated photothermolysis laser vs. 755 picosecond laser Not Applicable

Detailed Description:

This is a Clinical Trial comparing the 1,550-nanometer fractionated photothermolysis system laser to the 755 nanometer picosecond laser using a split-face (Right-Left) comparison. Both of these lasers are currently FDA approved for acne scarring.

Approximately 18 subjects, men and women with Fitzpatrick skin types I through V and facial acne scarring of grades III-IV (moderate to severe) will be enrolled. Both sides of the participants' face should have similar amount and severity of acne scarring. Participants will be over 18 years old. Patients have to be otherwise healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity.

Patients have to be overall healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity. Per PI discretion, any serious medical condition that may interfere with the study. In addition, patients who have been taking isotretinoin for a period of 6 months before treatment will be excluded.

Patients will have photographs taken at every visit prior to the laser treatments at week 0, week 4, and week 8. Photographs will also be taken at the week 24 follow-up visit. Photos will then be assessed by qualified blinded reviewers for comparison.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: All subjects will receive half of their faces treated with each laser. Subjects will be randomized to determine which side of the face is treated with each laser.
Masking: Single (Outcomes Assessor)
Masking Description: Blinded Assessors will be reviewing and scoring the photos after the study is completed.
Primary Purpose: Treatment
Official Title: Comparison of a 1,550 Nanometer Erbium: Glass Fractional Laser and 755-nanometer Alexandrite Picosecond Pulse Duration Laser With Diffractive Lens Array in the Treatment of Acne Scars: a Randomized, Split-face Trial
Actual Study Start Date : March 8, 2017
Actual Primary Completion Date : August 1, 2019
Estimated Study Completion Date : October 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Scars

Arm Intervention/treatment
Active Comparator: Right Side 1,550 laser Left Side 755 laser
All subjects on this arm will be treated on this split-faced. The Right side of their face will be treated with the 1,550-nanometer Fracionated Photothermolysis laser, and the left side of their face will be treated with the 755-nanometer alexandrite picosecond laser.
Device: 1,550 fracionated photothermolysis laser vs. 755 picosecond laser
All subjects will have one side of their face treated with one laser, and the other side with the other laser.

Active Comparator: Left Side 1,550 laser Right Side 755 laser
All subjects on this arm will be treated on this split-faced. The left side of their face will be treated with the 1,550-nanometer Fracionated Photothermolysis laser, and the right side of their face will be treated with the 755-nanometer alexandrite picosecond laser.
Device: 1,550 fracionated photothermolysis laser vs. 755 picosecond laser
All subjects will have one side of their face treated with one laser, and the other side with the other laser.




Primary Outcome Measures :
  1. To measure efficacy and safety of fractionated 1550-nanometer laser and 755-nanometer alexandrite picosecond laser in combination with a diffractive lens array, in treatment of moderate to severe acne scars. [ Time Frame: Photos will be taken at week 0, week 4, week 8, and week 24. ]
    Change in Baseline acne scarring compared to week 24 measured by photographic review. Measured by blinded reviewer assessments of photographs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women with Fitzpatrick skin types I through V and facial acne scarring of grades III-IV (moderate to severe) will be enrolled. Both sides of the participants' face should have similar amount and severity of acne scarring. Participants will be over 18 years old. Patients have to be otherwise healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity.

Exclusion Criteria:

  • Patients have to be overall healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity. Per PI discretion, any serious medical condition that may interfere with the study. In addition, patients who have been taking isotretinoin for a period of 6 months before treatment will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03988049


Locations
Layout table for location information
United States, Utah
University of Utah MidValley Dermatology
Murray, Utah, United States, 84107
Sponsors and Collaborators
David Smart
Investigators
Layout table for investigator information
Principal Investigator: David R Smart, MD University of Utah

Layout table for additonal information
Responsible Party: David Smart, Principal Investigator, University of Utah
ClinicalTrials.gov Identifier: NCT03988049     History of Changes
Other Study ID Numbers: IRB_00095294
First Posted: June 17, 2019    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertrophy
Pathological Conditions, Anatomical